- Home
- WEA vs TTRX Comparison
WEA vs TTRX Comparison
Compare WEA & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | TTRX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 116.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WEA | TTRX |
|---|---|---|
| Price | $10.69 | $3.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 29.3K | 13.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.16 | $2.57 |
| 52 Week High | $11.44 | $5.98 |
Technical Indicators
Market Signals| Indicator | WEA | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.42 | 50.51 |
| Support Level | $10.65 | $3.55 |
| Resistance Level | $10.87 | $4.01 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 23.53 | 49.26 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.